Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Capital Expenditures (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Capital Expenditures for 13 consecutive years, with $101000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 46.38% to $101000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $292000.0 through Dec 2025, up 79.14% year-over-year, with the annual reading at $292000.0 for FY2025, 79.14% up from the prior year.
  • Capital Expenditures for Q4 2025 was $101000.0 at Niagen Bioscience, up from $24000.0 in the prior quarter.
  • The five-year high for Capital Expenditures was $265000.0 in Q2 2021, with the low at $2000.0 in Q4 2021.
  • Average Capital Expenditures over 5 years is $67300.0, with a median of $43500.0 recorded in 2021.
  • The sharpest move saw Capital Expenditures crashed 99.26% in 2021, then skyrocketed 8500.0% in 2022.
  • Over 5 years, Capital Expenditures stood at $2000.0 in 2021, then surged by 8500.0% to $172000.0 in 2022, then plummeted by 87.79% to $21000.0 in 2023, then soared by 228.57% to $69000.0 in 2024, then soared by 46.38% to $101000.0 in 2025.
  • According to Business Quant data, Capital Expenditures over the past three periods came in at $101000.0, $24000.0, and $135000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.